Rationale for Therapeutic Silencing of Alpha-Synuclein in Parkinson’s Disease
The purpose of this paper is to provide the rationale for therapeutic silencing of the alpha-synuclein gene (SNCA) in Parkinson’s disease (PD). The paper reviews the public health significance of PD; the causal links between rare SNCA variants and familial PD; the association of common SNCA variants...
Main Author: | Demetrius M. Maraganore |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Movement Disorders Society
2011-05-01
|
Series: | Journal of Movement Disorders |
Subjects: | |
Online Access: | http://e-jmd.org/upload/jmd-4-1-1-1.pdf |
Similar Items
-
Targeting Alpha-Synuclein as a Therapy for Parkinson’s Disease
by: Carroll Rutherford Fields, et al.
Published: (2019-12-01) -
Identifying the Pathological Domain of Alpha- Synuclein as a Therapeutic for Parkinson’s Disease
by: Ning Shen, et al.
Published: (2019-05-01) -
Interaction between Neuromelanin and Alpha-Synuclein in Parkinson’s Disease
by: Shengli Xu, et al.
Published: (2015-06-01) -
Salivary alpha-synuclein (total and oligomeric form): potential biomarkers in Parkinson’s disease
by: Hala Shaheen, et al.
Published: (2020-02-01) -
Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinson’s Disease
by: Maria Angela Samis Zella, et al.
Published: (2019-01-01)